CMA secures director disqualification in pharmaceutical cartel proceedings
The Competition and Markets Authority has secured a competition disqualification undertaking by Mr Robin Davies, director of Alissa Healthcare Research Limited.
The disqualification undertaking relates to his involvement in breaches of UK and EU competition law in relation to the exchange of commercially sensitive information in connection with the drug nortriptyline. Alissa and King Pharma admitted to the illegal conduct and received fines of £174,912 and £75,573, respectively. Lexon did not settle and was fined £1.2 million.
The Company Directors Disqualification Act empowers the CMA to ask the court to disqualify a director from holding company directorships or performing certain roles for a specified period, if the director’s company has breached competition law.
Davies undertakes not to act as a director of any UK company for two years as of 24 November 2020.
Davies is the 18th director to agree to a director disqualification undertaking.
Separately, but arising out of the same competition law investigation the CMA has applied to the High Court to seek the disqualification of Mr Pritesh Sonpal, a director of Lexon (UK) Limited.
https://www.gov.uk/cma-cases/suppliers-of-antidepressants-director-disqualification
No comments:
Post a Comment